From lab to market
What it means, and what it does not
Proven: the device is tolerable, and across mild-to-moderate Alzheimer’s it did not beat a sham. Not yet shown: that it works in mild disease. The subgroup was planned in advance, but its p-values are unadjusted and the main result was negative. Suzanne Schindler of Washington University told Being Patient that a confirmatory trial in mild patients “would seem reasonable.”
Cognito is not waiting for one. Howell told IEEE Spectrum the company is on track to ask the US Food and Drug Administration for authorization in mild Alzheimer’s by mid-2027, through the De Novo route for new kinds of low-to-moderate-risk devices. His argument is that regulators weigh a device’s benefit against its risk, and this one’s risk is small.
For scale, the antibody drug lecanemab slowed decline on CDR-SB by 27 percent over 18 months, with brain swelling on scans in 12.6 percent of patients against 1.7 on placebo. Those numbers are not comparable with HOPE’s. One is a primary endpoint that was met. The other is a subgroup of a trial that missed.
The market has not waited either. A 40-hertz lamp from OptoCeutics sells for $2,999 as a wellness product, and a Vielight headset for $1,799. Neither is authorized to treat anything.
For the CTO. Any product whose effect depends on daily use has two efficacies: what it does when used, and how often it gets used. HOPE measured their product. If you ship software, wearables or anything else people must return to, your headline metric has the same hidden factor.
Timeline: FDA filing planned by mid-2027, per the company · open-label extension continuing · peer-reviewed publication not yet announced.
Field Notes · How a flicker is meant to treat a brain
1Pulse. Glasses flash and headphones click 40 times a second, as bright and loud as the wearer can tolerate.
2Entrain. Sensory neurons fire in step with the pulse, like a crowd clapping along to a drummer. Sound is added to carry the rhythm toward the hippocampus, a memory hub.
3Clear. In mice, the driven rhythm was followed by lower amyloid, protected synapses and faster flushing of waste fluid. Whether that chain holds in people is the open question.
Try it. Test five outcomes, each with a 5 percent chance of a false alarm. If they were independent, the chance that at least one lights up by luck is 1 − 0.955, about 23 percent. That is why unadjusted subgroup wins are treated as hints.
Glossary
Gamma rhythm. Fast, coordinated brain waves of roughly 30 to 100 cycles a second.
Entrainment. An outside rhythm pulling an oscillator into step with it.
Sham control. A look-alike device set not to treat; the placebo of the device world.
Per-protocol analysis. Counting only people who followed the rules. Informative, and easily biased.